文献速递眼整形与眼眶

IgG4相关性眼病患者对激素治疗反应及复发相关的临床血清学因素

Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease.
PubMed 文献 · Br J Ophthalmol · 2018-02-02

回顾性纳入2010年3月至2017年1月活检证实的28例IgG4相关性眼病(IgG4-ROD)患者,平均随访27.3个月。82%对全身激素治疗反应良好,但43%在初始激素治疗后复发。治疗前血清IgG4升高与完全反应相关(P=0.001),复发与治疗前血清IgG4升高(P=0.007)及初始激素疗程较短(P=0.042)相关。

要点

  • 82%的IgG4-ROD患者对全身激素治疗反应良好,但43%在初始治疗后复发。
  • 治疗前血清IgG4升高与初始激素完全反应相关(P=0.001),也与复发相关(P=0.007)。
  • 作者建议血清IgG4升高的患者可考虑全身激素低剂量维持治疗以避免复发。

核心结论

  • IgG4-ROD患者对全身激素治疗反应良好,但复发常见,尤其在治疗前血清IgG4升高和初始激素疗程较短的患者中。
  • 作者建议血清IgG4升高的患者可考虑全身激素低剂量维持治疗以避免复发。

研究设计与样本

  • 回顾性研究纳入2010年3月至2017年1月活检证实的28例IgG4-ROD患者,评估临床特征、血清IgG4水平、全身受累、治疗及结局、治疗反应和复发相关因素。

主要发现

  • 13例男性和15例女性(平均年龄50.8岁),平均随访27.3个月。
  • 治疗前血清IgG4升高(>1.35 g/L)9例(32%),全身性疾病18例(64%)。
  • 泪腺受累见于所有患者,22例(78.6%)为双侧受累。
  • 82%的患者对全身激素反应良好,但12例(43%)在初始激素治疗后复发,需要额外治疗以达到缓解。
  • 复发患者最终需要的激素总量显著多于无复发患者(P=0.011)。

关键数值与推荐

  • 初始激素治疗完全反应与治疗前血清IgG4升高(P=0.001)和双侧眼眶受累(P=0.050)相关。
  • 复发与治疗前血清IgG4升高(P=0.007)、初始激素剂量较低(P=0.057)和初始激素疗程较短(P=0.042)相关。

临床怎么用

  • 作者建议血清IgG4升高的患者可考虑全身激素低剂量维持治疗以避免复发。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To investigate the factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease (ROD). METHODS: Twenty-eight patients with biopsy-proven IgG4-ROD treated between March 2010 and January 2017 were included in this retrospective study. Clinical features, serum IgG4 levels, systemic involvement, treatments and treatment outcome, factors associated with response to treatment and recurrence were assessed. RESULT: Thirteen men and 15 women (mean age 50.8 years) were evaluated over mean follow-up period of 27.3 months. Elevated serum IgG4 levels (>1.35 g/L) and systemic disease were noted in 9 (32%) and 18 patients (64%), respectively. The lacrimal gland was involved in all patients, and 22 patients (78.6%) had bilateral involvement. Most patients (82%) responded well to systemic steroids, but 12 (43%) relapsed after the initial steroid treatment, requiring additional therapies to achieve remission. Complete response to initial steroid treatment was associated with elevated serum IgG4 levels before treatment (P=0.001) and bilateral orbital involvement (P=0.050). Recurrence was associated with elevated serum IgG4 levels before treatment (P=0.007), lower dose (P=0.057) and shorter duration of initial steroids (P=0.042). Patients with recurrence eventually required significantly more steroids than those without recurrence (P=0.011). CONCLUSIONS: Patients with IgG4-ROD responded well to systemic steroid treatment, but recurrence was common, particularly among those with elevated serum IgG4 levels and shorter duration of initial steroid treatment. Low-dose maintenance treatment with systemic steroids should be considered to avoid recurrence in patients with elevated serum IgG4 levels.

来源:Br J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Hong JW, Kang S, Song MK, et al. Clinicoserological factors associated with response to steroid treatment and recurrence in patients with IgG4-related ophthalmic disease. Br J Ophthalmol. 2018. PMID: 29420193. doi:10.1136/bjophthalmol-2017-311519

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。